Table 2. The relationships between AFU levels and baseline characteristics in patients with stage T1N0 ESCC.
Characteristic | AFU ≤17.95 (n=52) | AFU >17.95 (n=108) | P* |
---|---|---|---|
Gender | 0.900 | ||
Male | 39 | 80 | |
Female | 13 | 28 | |
Age (years) | 0.069 | ||
<65 | 29 | 76 | |
≥65 | 23 | 32 | |
Smoking history | 0.019 | ||
Yes | 21 | 65 | |
No | 31 | 43 | |
Alcohol consumption | 0.123 | ||
Yes | 4 | 18 | |
No | 48 | 90 | |
Performance status | 0.115 | ||
0 | 45 | 99 | |
1 | 5 | 9 | |
2 | 2 | 0 | |
Differentiation | 0.582 | ||
Well | 10 | 14 | |
Moderate | 26 | 58 | |
Poor | 16 | 36 | |
Tumor location | 0.932 | ||
Upper | 9 | 17 | |
Middle | 34 | 70 | |
Lower | 9 | 21 | |
Length of tumor, cm | 0.893 | ||
≤1.8 | 14 | 28 | |
<1.8 | 38 | 80 | |
Surgical approach | 0.958 | ||
Sweet | 33 | 69 | |
McKeown | 19 | 39 | |
Reconstructed organ | |||
Gastric tube | 52 | 107 | – |
Anastomosis | 0.759 | ||
Hand-sewn | 5 | 12 | |
Stapled | 47 | 95 | |
Depth of tumor invasion | 0.065 | ||
T1a | 17 | 21 | |
T1b | 35 | 87 | |
Adjuvant therapy | 0.965 | ||
Yes | 2 | 4 | |
No | 50 | 104 | |
Resected lymph nodes count (mean ± SD) | 19.4±11.2 | 20.1±12.1 | 0.676 |
Resected lymph nodes stations (mean ± SD) | 6.48±3.50 | 6.11±3.36 | 0.644 |
ALT | 0.012 | ||
≤18.55 | 36 | 52 | |
>18.55 | 16 | 56 | |
AST | 0.581 | ||
≤15.35 | 10 | 17 | |
>15.35 | 42 | 91 | |
ALT/AST | 0.063 | ||
≤0.75 | 21 | 28 | |
>0.75 | 31 | 80 | |
GGT | 0.005 | ||
≤21.85 | 35 | 47 | |
>21.85 | 17 | 61 | |
LDH | 0.971 | ||
≤170.20 | 35 | 73 | |
>170.20 | 17 | 35 |
*, P value less than 0.05 indicated a statistically significant difference. ESCC, esophageal squamous cell carcinoma; OS, overall survival; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; LDH, lactate dehydrogenase; AFU, alpha-l-fucosidase.